Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex-C for prevention of infections in secondary antibody deficiency associated with CLL, multiple myeloma, or non-Hodgkin lymphoma
2026-526803-31-00Phase 3Authorised
- Sponsor
- Grifols
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of immune globulin in secondary hypogammaglobulinemia, sponsored by Grifols. Primary endpoint: Serious bacterial infection rate per participant per year. Planned start Oct 2026; status: authorised.
02
Drugs
immune globulin
03
Conditions
secondary hypogammaglobulinemia
Beyond the preview
Go deeper on 2026-526803-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526803-31-00.